Can favipiravir help treat COVID-19?

Can favipiravir help treat COVID-19?

Favipiravir, an antiviral drug used for influenza in Japan, is currently being studied in humans for treating COVID-19 in over 30 clinical trials (as of Octoboer 26, 2020). It is not known whether it is safe or helpful for this disease. Sometimes new treatment ideas turn out to help, and sometimes they are actually proven to be harmful. The best way to learn how to treat COVID-19 is to conduct randomized controlled clinical trials. You can search for in-progress clinical trials at trialstoday.org.

What are the side effects of favipiravir?

Favipiravir side effects. Some common side effects of the Fabiflu are swelling all over the body, muscle pain, asthma attack, gastrointestinal upset, miscarriages, hay fever, and allergic dermatitis. The use of favipiravir in pregnancy is restricted as it may cause fetal damage. Warnings and Precautions.

Does favipiravir reduce mortality in covid-19 patients?

The mortality rate in the Favipiravir group was approximately 30% less than the control group, but this finding not statistically significant. Favipiravir possibly exerted no significant beneficial effect in the term of mortality in the general group of patients with mild to moderate COVID-19.

What is the mechanism of action of funfavipiravir?

Favipiravir is a pyrazinecarboxamide derivative with activity against RNA viruses. Favipiravir is converted to the ribofuranosyltriphosphate derivative by host enzymes and selectively inhibits the influenza viral RNA-dependent RNA polymerase. Favipiravir is a member of pyrazines and a primary carboxamide.

Does favipiravir require supplemental oxygen therapy?

Requiring supplemental oxygen therapy in the Favipiravir group was 7% less than the control group, (RR = 0.93, 95% CI: 0.67–1.28; P = 0.664). Transferred to ICU and adverse events were not statistically different between two groups.